ADAURA Trial; Early Stage Non–Small Cell Lung Cancer
0 Views
administrator
07/14/23
Joshua Bauml, MD, reviews the phase 3 ADAURA trial for adjuvant osimertinib for early stage EGFR-positive non–small cell lung cancer.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive
-
Category
Show more
Facebook Comments
No comments found